Quantcast
Home > Quotes > NVUS

Novus Therapeutics, Inc. Common Stock (NVUS) Quote & Summary Data

NVUS 
$3.72
*  
0.28
7%
Get NVUS Alerts
*Delayed - data as of Nov. 20, 2018  -  Find a broker to begin trading NVUS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    NVUS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
9.5
Today's High / Low
$ 4.03 / $ 3.58
Share Volume
2,622
50 Day Avg. Daily Volume
40,729
Previous Close
$ 4
52 Week High / Low
$ 8.61 / $ 3.12
Market Cap
35,050,372
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
2,622
50 Day Avg. Daily Volume:
40,729

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.12

Trading Range

The current last sale of $3.72 is 19.23% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.03 $ 8.61
 Low: $ 3.58 $ 3.12

Company Description (as filed with the SEC)

Novus Therapeutics is a specialty pharmaceutical company focused on developing products for disorders of the ear, nose, and throat (ENT). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. The company's lead product (OP-02) is a surfactant-based, combination drug product being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). Globally, OM affects more than 700 million adults and children every year. OM is a common disorder seen in pediatric practice, and in the United States is the most frequent reason children are prescribed antibiotics and undergo surgery. Novus also has a foam-based drug delivery technology (OP-01), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities.  ... More ...  


Risk Grade

Where does NVUS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.85
Open Date:
Nov. 20, 2018
Close Price:
$ 3.72
Close Date:
Nov. 20, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x